Optomed Oyj Future Growth

Future criteria checks 5/6

Optomed Oyj is forecast to grow earnings and revenue by 64.6% and 28% per annum respectively while EPS is expected to grow by 76.1% per annum.

Key information

64.6%

Earnings growth rate

76.1%

EPS growth rate

Medical Equipment earnings growth25.0%
Revenue growth rate28.0%
Future return on equityn/a
Analyst coverage

Low

Last updated27 Sep 2024

Recent future growth updates

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

May 11
Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

Recent updates

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Sep 27
Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

May 11
Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

May 10
Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Mar 22
Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Feb 18
Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Dec 21
Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Nov 15
Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Aug 09
Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Jun 01
Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Oct 27
Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Is Optomed Oyj (HEL:OPTOMED) A Risky Investment?

Apr 23
Is Optomed Oyj (HEL:OPTOMED) A Risky Investment?

Optomed Oyj (HEL:OPTOMED) Has Debt But No Earnings; Should You Worry?

Aug 05
Optomed Oyj (HEL:OPTOMED) Has Debt But No Earnings; Should You Worry?

Earnings and Revenue Growth Forecasts

HLSE:OPTOMED - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202629-1-251
12/31/202522-4-312
12/31/202415-6-2-32
6/30/202415-5-3-1N/A
3/31/202415-4-3-1N/A
12/31/202315-4-3-1N/A
9/30/202315-4-30N/A
6/30/202315-5-4-2N/A
3/31/202315-5-5-2N/A
12/31/202215-5-5-2N/A
9/30/202214-6-6-3N/A
6/30/202214-5-6-3N/A
3/31/202214-5-6-3N/A
12/31/202115-4-6-3N/A
9/30/202115-3-4-2N/A
6/30/202115-2-4-2N/A
3/31/202114-3-20N/A
12/31/202013-3-5-3N/A
9/30/202013-3-3-1N/A
6/30/202013-4-3-1N/A
3/31/202015-4-4-2N/A
12/31/201915-3-10N/A
9/30/201916-2-20N/A
12/31/201814-1-20N/A
12/31/20177-3N/A-1N/A
12/31/20167-3N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPTOMED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: OPTOMED is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OPTOMED is expected to become profitable in the next 3 years.

Revenue vs Market: OPTOMED's revenue (28% per year) is forecast to grow faster than the Finnish market (2.3% per year).

High Growth Revenue: OPTOMED's revenue (28% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPTOMED's Return on Equity is forecast to be high in 3 years time


Discover growth companies